Increased Derived Time in Range Is Associated with Reduced Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and Microvascular Events in Type 2 Diabetes: A Post Hoc Analysis of DEVOTE-Reference-Cited by-同舟云学术

Increased Derived Time in Range Is Associated with Reduced Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and Microvascular Events in Type 2 Diabetes: A Post Hoc Analysis of DEVOTE

Published:2023-06-01 Issue:6 Volume:25 Page:378-383
ISSN:1520-9156
Container-title:Diabetes Technology & Therapeutics
language:en
Short-container-title:Diabetes Technology & Therapeutics

Author:

Bergenstal Richard M.¹^ORCID,Hachmann-Nielsen Elise²,Kvist Kajsa³,Peters Anne L.⁴^ORCID,Tarp Jens Magelund³,Buse John B.⁵

Affiliation:

1. International Diabetes Center, HealthPartners Institute, 3800 Park Nicollet Blvd, Minneapolis, Minnesota, USA.

2. Clinical Drug Development, Novo Nordisk A/S, Søborg, Denmark.

3. Data Science, Novo Nordisk A/S, Søborg, Denmark.

4. Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.

5. Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.

Publisher

Mary Ann Liebert Inc

Subject

Medical Laboratory Technology,Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/dia.2022.0447

Reference18 articles.

1. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials

2. International Consensus on Use of Continuous Glucose Monitoring

3. Continuous Glucose Monitoring: A Consensus Conference of the American Association of Clinical Endocrinologists and American College of Endocrinology

4. Time in Range Is Associated with Carotid Intima-Media Thickness in Type 2 Diabetes

5. Proportion of time spent in blood glucose range 70 to 140 mg/dL is associated with increased survival in patients admitted to ICU after cardiac arrest

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Time‐in‐range derived from self‐measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: A participant‐level pooled analysis of three phase 3 LixiLan randomized controlled trials;Diabetes, Obesity and Metabolism;2024-09-08

2. Long-Term Improvements in Glycemic Control with Dexcom CGM Use in Adults with Noninsulin-Treated Type 2 Diabetes;Diabetes Technology & Therapeutics;2024-06-21

3. Time in range prediction using the experimental mobile application in type 1 diabetes;Diabetes mellitus;2024-06-06

4. Utility of time in tight range (TITR) in evaluating metabolic control in pediatric and adult patients with type 1 diabetes in treatment with advanced hybrid closed-loop systems;Endocrine;2024-05-30

5. Research progress on the association between glycemic variability index derived from CGM and cardiovascular disease complications;Acta Diabetologica;2024-03-12